Vivani Medical (NASDAQ:VANI) Director Gregg Williams Buys 1,587,301 Shares

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,587,301 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the transaction, the director owned 34,531,785 shares in the company, valued at approximately $43,510,049.10. The trade was a 4.82% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Gregg Williams also recently made the following trade(s):

• On Wednesday, April 15th, Gregg Williams bought 1,587,301 shares of Vivani Medical stock. The shares were bought at an average cost of $1.26 per share, for a total transaction of $1,999,999.26.
• On Sunday, March 15th, Gregg Williams bought 1,575,231 shares of Vivani Medical stock. The shares were bought at an average cost of $1.07 per share, for a total transaction of $1,685,497.17.

Vivani Medical Stock Performance

NASDAQ VANI opened at $1.15 on Wednesday. The company has a market cap of $99.18 million, a P/E ratio of -2.87 and a beta of 2.35. The business’s 50 day moving average price is $1.18 and its 200-day moving average price is $1.29. Vivani Medical, Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $1.92.

Vivani Medical (NASDAQ:VANI) last released its earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). As a group, equities analysts predict that Vivani Medical, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their target price on Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.50.

Hedge Funds Weigh In On Vivani Medical

Several hedge funds have recently bought and sold shares of VANI. Citadel Advisors LLC bought a new position in Vivani Medical in the 3rd quarter valued at $26,000. Susquehanna International Group LLP grew its position in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares during the last quarter. Jane Street Group LLC bought a new position in Vivani Medical in the 4th quarter valued at $60,000. Renaissance Technologies LLC grew its position in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after acquiring an additional 53,127 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Vivani Medical in the 4th quarter valued at $174,000. Institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.